Advancing our innovative pipeline
to address unmet needs

Overview

We are applying our TransCon technology to build a fully integrated, rare disease-focused biopharmaceutical company with a diversified pipeline of long-acting prodrug therapies that address unmet needs.

Ascendis Internal Endocrinology Pipeline Strategic Collaborations TransCon GH TransCon PTH TransCon CNP > $3 billion 2 > $2 billion 3 > $1 billion Product Candidate Preclinical Phase 1 Phase 2 Phase 3 Potential WW Market 1 Worldwide Commerical Rights Pediatric Growth Hormone Deficiency Adult Growth Hormone Deficiency Hypoparathyroidism Achondroplasia TransCon Anti-VEGF TransCon Peptides > $7 billion > $1 billion Not disclosed Not disclosed Ophthalmology Diabetes Product Candidate Primary Indication Development Stage Potential WW Market 1 Worldwide Commerical Rights

1Based on market data and Company estimates

2Includes all indications

3Based on treatment of ~25% of the U.S. patient population of ~80,000 patients